dc.creator | Melagraki G., Leonis G., Ntougkos E., Rinotas V., Papaneophytou C., Mavromoustakos T., Kontopidis G., Douni E., Kollias G., Afantitis A. | en |
dc.date.accessioned | 2023-01-31T08:58:38Z | |
dc.date.available | 2023-01-31T08:58:38Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.2174/1568026618666180607084430 | |
dc.identifier.issn | 15680266 | |
dc.identifier.uri | http://hdl.handle.net/11615/76492 | |
dc.description.abstract | The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn’s disease, refractory asthma, and multiple sclerosis. Receptor Activator of Nuclear Factor Kappa- B Ligand (RANKL) belongs to the TNF family and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Malfunction among RANK/RANKL/OPG can also result in bone loss diseases, including postmenopausal osteoporosis, rheumatoid arthritis, bone metastasis and multiple myeloma. To disrupt the unwanted functions of TNF and RANKL, current attempts focus on blocking TNF and RANKL binding to their receptors. In this review, we present the research efforts toward the development of low-molecular-weight pharmaceuticals that directly block the detrimental actions of TNF and RANKL. © 2018 Bentham Science Publishers. | en |
dc.language.iso | en | en |
dc.source | Current Topics in Medicinal Chemistry | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050592640&doi=10.2174%2f1568026618666180607084430&partnerID=40&md5=a2a60e5bdd02ae48a91f3f8a40b92b03 | |
dc.subject | abd 056 | en |
dc.subject | abd 328 | en |
dc.subject | biphenylcarboxylic acid derivative | en |
dc.subject | compound T23 | en |
dc.subject | compound T8 | en |
dc.subject | denosumab | en |
dc.subject | dmbo | en |
dc.subject | erythrosine | en |
dc.subject | iw 927 | en |
dc.subject | natural product | en |
dc.subject | osteoclast differentiation factor inhibitor | en |
dc.subject | protein inhibitor | en |
dc.subject | saponin | en |
dc.subject | spd 304 | en |
dc.subject | spd 304 derivative | en |
dc.subject | suramin | en |
dc.subject | tumor necrosis factor | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | tumor necrosis factor receptor | en |
dc.subject | unclassified drug | en |
dc.subject | ligand | en |
dc.subject | protein binding | en |
dc.subject | receptor activator of nuclear factor kappa B | en |
dc.subject | tumor necrosis factor | en |
dc.subject | antiproliferative activity | en |
dc.subject | bone cancer | en |
dc.subject | computer model | en |
dc.subject | drug design | en |
dc.subject | drug isolation | en |
dc.subject | drug mechanism | en |
dc.subject | drug potency | en |
dc.subject | drug protein binding | en |
dc.subject | drug research | en |
dc.subject | drug screening | en |
dc.subject | drug structure | en |
dc.subject | drug synthesis | en |
dc.subject | human | en |
dc.subject | liver cancer | en |
dc.subject | molecular docking | en |
dc.subject | molecular dynamics | en |
dc.subject | multiple myeloma | en |
dc.subject | nonhuman | en |
dc.subject | onchocerciasis | en |
dc.subject | osteoporosis | en |
dc.subject | protein analysis | en |
dc.subject | protein expression | en |
dc.subject | protein function | en |
dc.subject | protein protein interaction | en |
dc.subject | Review | en |
dc.subject | trypanosomiasis | en |
dc.subject | virtual reality | en |
dc.subject | animal | en |
dc.subject | antagonists and inhibitors | en |
dc.subject | chemistry | en |
dc.subject | drug effect | en |
dc.subject | molecular library | en |
dc.subject | molecular model | en |
dc.subject | molecular weight | en |
dc.subject | pharmacology | en |
dc.subject | synthesis | en |
dc.subject | Animals | en |
dc.subject | Humans | en |
dc.subject | Ligands | en |
dc.subject | Models, Molecular | en |
dc.subject | Molecular Weight | en |
dc.subject | Protein Binding | en |
dc.subject | Receptor Activator of Nuclear Factor-kappa B | en |
dc.subject | Small Molecule Libraries | en |
dc.subject | Tumor Necrosis Factors | en |
dc.subject | Bentham Science Publishers B.V. | en |
dc.title | Current status and future prospects of small–molecule protein–protein interaction (PPI) inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-κB ligand (RANKL) | en |
dc.type | other | en |